Akebia Therapeutics Q2 revenue smashes expectations

Reuters

Aug 07

Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> revenue smashes expectations

Overview

Akebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectations
Net income for Q2 2025 beats estimates, reaching $0.2 mln
Company expands Vafseo prescribing access through dialysis partnerships

Result Drivers

VAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptions
DIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3
REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$62.47 mln	$47.20 mln (5 Analysts)
Q2 EPS			-$0.02 (4 Analysts)
Q2 Net Income	Beat	$247,000	-$4.67 mln (4 Analysts)
Q2 Operating Income	Beat	$14.09 mln	$2.03 mln (3 Analysts)
Q2 Basic EPS
Q2 Operating Expenses		$38.46 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its August 6 closing price of $3.79

Press Release: ID:nGNX86RVjh

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557255044"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557255044\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557255044?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557255044","market":"nz","top_or_hot":-1,"title":"Akebia Therapeutics Q2 revenue smashes expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue smashes expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Akebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectations</p></li><li><p>Net income for Q2 2025 beats estimates, reaching $0.2 mln</p></li><li><p>Company expands Vafseo prescribing access through dialysis partnerships</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>VAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptions</p></li><li><p>DIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3</p></li><li><p>REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$62.47 mln</p></td><td><p>$47.20 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td></td><td><p>-$0.02 (4 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Beat</p></td><td><p>$247,000</p></td><td><p>-$4.67 mln (4 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Beat</p></td><td><p>$14.09 mln</p></td><td><p>$2.03 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$38.46 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its August 6 closing price of $3.79</p></li></ul><p>Press Release: <span>ID:nGNX86RVjh</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics Q2 revenue smashes expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics Q2 revenue smashes expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue smashes expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Akebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectations</p></li><li><p>Net income for Q2 2025 beats estimates, reaching $0.2 mln</p></li><li><p>Company expands Vafseo prescribing access through dialysis partnerships</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>VAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptions</p></li><li><p>DIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3</p></li><li><p>REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$62.47 mln</p></td><td><p>$47.20 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td></td><td><p>-$0.02 (4 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Beat</p></td><td><p>$247,000</p></td><td><p>-$4.67 mln (4 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Beat</p></td><td><p>$14.09 mln</p></td><td><p>$2.03 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$38.46 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its August 6 closing price of $3.79</p></li></ul><p>Press Release: <span>ID:nGNX86RVjh</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVA","symbol_name":"达维塔保健","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX15F5DF:1","article_id":"2557255044","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557255044","pubTimestamp":1754566555,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akebia Therapeutics Q2 revenue smashes expectationsOverviewAkebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectationsNet income for Q2 2025 beats estimates, reaching $0.2 mlnCompany expan","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DVA":"达维塔保健","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"Akebia Therapeutics第二季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":0.9,"DVA":0.9},"content_text":"Akebia Therapeutics Q2 revenue smashes expectationsOverviewAkebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectationsNet income for Q2 2025 beats estimates, reaching $0.2 mlnCompany expands Vafseo prescribing access through dialysis partnershipsResult DriversVAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptionsDIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%Key DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$62.47 mln$47.20 mln (5 Analysts)Q2 EPS-$0.02 (4 Analysts)Q2 Net IncomeBeat$247,000-$4.67 mln (4 Analysts)Q2 Operating IncomeBeat$14.09 mln$2.03 mln (3 Analysts)Q2 Basic EPSQ2 Operating Expenses$38.46 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its August 6 closing price of $3.79Press Release: ID:nGNX86RVjh(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}